EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer

• Published in: Diagnostics (Basel) Vol. 12; no. 2; p. 366
• Main Authors: Nikas, Ilias, Giaginis, Constantinos, Petrouska, Kalliopi, Alexandrou, Paraskevi, Michail, Artemis, Sarantis, Panagiotis, Tsourouflis, Gerasimos, Danas, Eugene, Pergaris, Alexandros, Politis, Panagiotis K, Nakopoulou, Lydia, Theocharis, Stamatios
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2022; MDPI
• Subjects: Antibodies; Antigens; basal-like breast cancer; biomarker; Biomarkers; Breast cancer; Cancer therapies; Chemotherapy; EPH; ephrin; Epidermal growth factor; Gene expression; Kinases; Lymphatic system; Medical prognosis; Metastasis; Patients; Penicillin; targeted therapy; Thyroid gland; United States > US; basal-like breast cancer; targeted therapy; EPH; biomarker; ephrin
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics12020366

Ongoing research continues to elucidate the complex role of ephrin receptors (EPHs) and their ligands (ephrins) in breast cancer pathogenesis, with their varying expression patterns implied to have an important impact on patients' outcome. The current study aims to investigate the clinical significance of EPHA2, EPHA4, and EPHA7 expression in triple-negative breast cancer (TNBC) cases. EPHA2, EPHA4, and EPHA7 protein expression was assessed immunohistochemically on formalin-fixed and paraffin-embedded (FFPE) TNBC tissue sections from 52 TNBC patients and correlated with key clinicopathologic parameters and patients' survival data (overall survival (OS); disease-free survival (DFS)). EPHA2, EPHA4, and EPHA7 expression was further examined in TNBC cell lines. EPHA2 overexpression was observed in 26 (50%) of the TNBC cases, who exhibited a shorter OS and DFS than their low-expression counterparts, with EPHA2 representing an independent prognostic factor for OS and DFS ( = 0.0041 and = 0.0232, respectively). EPHA4 overexpression was associated with lymph node metastasis in TNBC patients ( = 0.0546). Alterations in EPHA2, EPHA4, and EPHA7 expression levels were also noted in the examined TNBC cell lines. Our study stresses that EPHA2 expression constitutes a potential prognostic factor for TNBC patients. Given the limited treatment options and poorer outcome that accompany the TNBC subtype, EPHA2 could also pose as a target for novel, more personalized, and effective therapeutic approaches for those patients.